A phase I/II study of Cisplatin, Amrubicin plus irradiation for Limited disease small cell lung cancer

A phase I/II study of Cisplatin, Amrubicin plus irradiation for Limited disease small cell lung cancer - A phase I/II study of Cisplatin, Amrubicin plus irradiation for Limited disease small cell lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005816

Enrollment

Registered

2011-06-20

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

Amurubicin/Cisplatin plus irradiation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histological or cytological diagnosis of lung cancer (2)untreated patient (3)Limited disease (4)Patients without active double cancer (5)Age 70 years or younger (6)ECOG Performance status :0-1 (7)Patients with adequate organ function WBC 4000/mm3 or more,Hb 10.0g/dl,Plt 100000/mm3 more,T. Bil 1.5mg/dl or less ,AST,ALT 2 times the upper limit of normal for the facility,sCr<the upper limit of normal for the facility (8)Provided written consent in person for participation in this study

Exclusion criteria

Exclusion criteria: (1)stage IA (2)accumulated cardiac effusion (3)accumulated pleural effusion (4)Patients with active severe infections (5)Women during pregnancy (6)Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression Free Survival Overall survival Toxicity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026